title: What next for newly diagnosed glioblastoma?
abstract: Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune™) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.
authors.affiliation: Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Evidio
authors.initials: E
authors.lastname: Domingo-Musibay
authors.affiliation: Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.|Department of Molecular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Evanthia
authors.initials: E
authors.lastname: Galanis
mesh_terms: D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis / Q000628:therapy*; D000066491:Clinical Decision-Making; D003131:Combined Modality Therapy / Q000379:methods; D019468:Disease Management; D015316:Genetic Therapy; D005909:Glioblastoma / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D050130:Oncolytic Virotherapy; D059039:Standard of Care
chemical_list: D020533:Angiogenesis Inhibitors
keywords: bevacizumab; glioblastoma; newly diagnosed; novo-TTF; radiation therapy; temozolomide